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Neurological complications may happen during treatment of childhood hematologic 
malignancies and solid tumors, of which headache and seizures are the most 
common (1).
In 1996, Hinchey et al. described the clinical entity of reversible posterior 
leukoencephalopathy syndrome (1-3). It is also known as posterior reversible 
encephalopathy syndrome (PRES) or posterior reversible leukoencephalopathy 
syndrome. This syndrome was recognized since magnetic resonance imaging (MRI) 
became available. Typical transient lesions on MRI (i.e., edema of the subcortical 
white matter shown on T2 weighted images and fluid attenuation inversion recovery 
(FLAIR) images) are pathognomonic of the syndrome. In addition, PRES can affect 
basal ganglia, cerebellar hemispheres, and brainstem (1). The main clinical features 
of this syndrome are headaches, seizures, altered levels of mental status, and cortical 
blindness (1). These clinical and radiographic perturbations are transient, and 
patient’s outcome is usually favorable (1-3). 
PRES has been initially described in adult patients with eclampsia, renal dysfunction, 
and systemic lupus erythematosus (SLE), and a robust association with severe 
hypertension and immunosuppression was described. Also, PRES is a clinico-
radiological phenomenon, which is associated with various medical conditions 
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Objective 
Posterior reversible encephalopathy syndrome (PRES) is a clinico-
neuroradiological disease entity, which is represented by characteristic 
magnetic resonance imaging (MRI) findings of subcortical/cortical 
hyperintensity in T2-weighted sequences. It is more often seen in parietal-
occipital lobes, and is accompanied by clinical neurological changes. PRES is 
a rare central nervous system (CNS) complication in patients with childhood 
hematologic-oncologic disese and shows very different neurological symptoms 
between patients, ranging from numbness of extremities to generalized seizure.
In this article, we will review PRES presentation in hematologic-oncologic 
patients. Then, we will present our patient, a 7-year-old boy with Evans syndrome 
on treatment with cyclosporine, mycophenolate mofetil (MMF) and prednisone, 
with seizure episodes and MRI finding in favour of PRES. 
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in children with hematologic and malignant disease 
including leukemia, solid tumors, aplastic anemia, and 
autoimmune disease. Understanding of this syndrome 
and its sequelae in this population is limited by the 
small number of reported patients and by an incomplete 
understanding of the disorder itself (1, 3, 4-6).
In this article, we will review literature about PRES, 
all well-documented PRES cases during childhood 
cancer and hematologic disorders, and then we present 
a 7-year-old boy with Evans syndrome who developed 
PRES during the immunosuppressive treatment.
PRES Epidemiology
The global incidence of PRES is unknown. The only 
epidemiological data are from retrospective studies 
of cases seen between 1988 and 2008. PRES has 
been reported in patients aged 4 to 90 years. There is 
a significant female predominance which may reflect 
some of the causes. Many patients with PRES have 
comorbidities that may be severe conditions, e.g., bone 
marrow or solid organ transplantation, chronic renal 
failure, and chronic hypertension (7).
Pathophysiology
The pathophysiology of PRES has been remained 
controversial until now. The two main hypotheses 
contradict each other. One is impaired cerebral 
autoregulation that is responsible for an increase 
in cerebral blood flow (CBF), while another is 
endothelial dysfunction with cerebral hypoperfusion. 
This hypoperfusion hypothesis may be most related 
to cases of PRES associated with cytotoxic therapy. 
In both hypotheses, the outcome of the cerebral 
blood perfusion abnormalities is blood brain barrier 
dysfunction with cerebral vasogenic edema. Onder et 
al. detected hypertensive crisis as the most common 
trigger of PRES in 59%. PRES related to hypertension 
might be due to sudden increase in blood pressure 
causing disruption of the autoregulatory mechanisms 
of the CNS vasculature, which causes vasoconstriction 
and vasodilatation, and breakdown of the blood-
brain barrier. The immunosuppressive and cytotoxic 
drugs may cause and aggravate hypertension and may 
decrease seizure threshold. Intrathecal chemotherapy 
may cause cerebral vasospasm, which contributes to 
cerebral vascular autoregulation impairment. Also, it 
appears that renal dysfunction predisposes to PRES, 
because of chronic uremia or fluid overload. One of 
the most important immunosuppressive drugs that can 
induce PRES is cyclosporine. The distribution of T2 
abnormalities in cyclosporine-induced PRES can be 
related to the sparse sympathetic innervation in the 
posterior circulation. Pathologic studies have revealed 
that the relative density of sympathetic innervation 
is greatest in the internal carotid and anterior cerebral 
territories and least in the basilar artery and its branches. 
Hence, breakdown of autoregulatory mechanisms would 
first occur in the more poorly innervated vessels of the 
posterior circulation (1,6,7-15).
Conditions most commonly associated with PRES:
Toxic Agents: 
Cytotoxic agents: Alkyl ating agents
Cisplatin, Oxaliplatin, Carboplatin 




Anti-angiogenic agents: Bevacizumab, Sunitinib
Immunomodulatory cytokines: Interferon-alpha, 
Interleukin-2 






Anticalcineurin agents: Cyclosporine A, Tacrolimus 
(FK 506), 
Sirolimus
High-dose corticosteroid therapy (e.g., dexamethasone 
and methylprednisolone) 
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Computed  tomography  (CT)  findings are often normal or nonspecific. Hypodensities  in a 
suggestive  topographic  distribution  suggest  PRES.  Cerebral  MRI  is  the  important 
investigation  for  the  diagnosis  of  PRES.  Proton‐density  and  T2‐weighted  images  show 
regions  of  high  signal  indicating  edema.  Fluid‐attenuated  inversion  recovery  (FLAIR) 
sequences also visualize the  lesions. The application of FLAIR has been shown to  improve 
the  diagnosis  of  PRES  and  the  detection  of  subcortical  and  cortical  lesions  in  PRES.  T1‐









Stem cell transplantation, solid organ
Other Conditions
Sickle cell disease, Guillain-Barré syndrome, 
hypomagnesaemia, hypercalcemia, tumor lysis 
syndrome, porphyria, pheochromocytoma, and 
Cushing syndrome (7).
Clinical Manifestations of PRES
The typical features of PRES include consciousness 
impairment, seizure activity, headaches, visual 
abnormalities, nausea/vomiting, and focal neurological 
deficit (7). Consciousness impairment may range in 
severity from confusion, somnolence, and lethargy to 
encephalopathy or coma. All these clinical features do 
not describe in all pediatric PRES patients. In a study on 
25 children with PRES, 44% manifested all four clinical 
symptoms, 32% demonstrated three, 16% showed two, 
and 8% had only one symptom. Kwon et al. reported 
12 patients that presented with seizures (42%), visual 
disturbances (33%), headache (17%), or altered mental 
status (8%).  Incecik et al. detected the most common 
clinical features as seizure (6/9), headache (6/9), and 
altered consciousness (4/9). The other symptoms were 
nausea and vomiting and blurred vision (7,12).
Diagnosis
PRES is a clinico-radiological entity. The intensity 
and severity of its clinical manifestations are different 
and may need ICU admission. Imaging findings also 
vary in severity. Complete familiarity with the imaging 
criteria is essential for the diagnosis. Suggestive clinical 
manifestations together with radiological criteria 
establishe the diagnosis of PRES. In suspicious cases, 
the clinical and radiological improvement that occurs 
once appropriate treatment is given, confirms the 
diagnosis. However, there are no consensual guidelines 
for validation of PRES diagnosis (1, 2, 7).
Roles for computed tomography and MRI in the 
diagnosis of PRES
Computed tomography (CT) findings are often 
normal or nonspecific. Hypodensities in a suggestive 
topographic distribution suggest PRES. Cerebral MRI is 
the important investigation for the diagnosis of PRES. 
Proton-density and T2-weighted images show regions of 
high signal indicating edema. Fluid-attenuated inversion 
recovery (FLAIR) sequences also visualize the lesions. 
The application of FLAIR has been shown to improve 
the diagnosis of PRES and the detection of subcortical 
and cortical lesions in PRES. T1-weighted images 
demonstrate low-intensity foci. Diffusion-weighted 
imaging (DWI) is normal but the apparent diffusion 
coefficient is enhanced. Finally, enhancement is seen in 
approximately half the cases. MRI is more preferable 
than CT for the diagnosis of PRES (7). 
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Fig 1. MRI in patient with PRES: Typical hyperintense 
spots at cortical-subcortical level in T2-weighted 
sequences in parietal and occipital regions (white arrows)
Fig 2. FLAIR MRI demonstrating bilateral zones of 
subcortical white matter hypersignal in the posterior 
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Fluid-attenuated inversion recovery (FLAIR) sequence 
showing bilateral high-signal foci in the cerebellum, 
basal ganglia, and occipital, parietal, frontal, and 
temporal lobes (1-4,7).
Fig 3. FLAIR MRI demonstrating resolution of 
hypersignal zones
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Fig 4. T2-weighted MRI of the brain demonstrating 










Radiological Characteristics of PRES (7)
Until recently, It was believed that PRES  consistently 
produce bilateral and symmetric regions of edema 
typically located in the white matter and predominating 
in the posterior parietal and occipital lobes. Sometimes, 
edema has been described in the frontal lobes, temporal, 
basal ganglia or cerebellum and brainstem in the 
posterior fossa, and cortical gray matter.
The four radiological patterns of PRES are as below:
a. Holohemispheric watershed pattern (23%) 
(Fig.6a). A swath of confluent vasogenic edema 
extends through the frontal, parietal, and occipital 
lobes. Involvement of the temporal lobes is less 
noticeable This topography matches the watershed 
zone between the anterior and posterior cerebral 
arteries, on the one hand, and the middle cerebral 
artery, on the other.
b. Superior frontal sulcus pattern (27%) (Fig.6b). 
Patchy edema predominates in the frontal lobes 
along the superior frontal sulci. The parietal and 
occipital lobes are involved variably.
c. Dominant parietal-occipital pattern (22%) (Fig.6c). 
In this pattern that was previously thought to be 
typical of PRES, the posterior part of the parietal 
and occipital lobes is predominantly involved. The 
edema alters in severity from mild to extensive.
d. Partial or asymmetric expression of the primary 
patterns (28%) (Fig.6d). The partial form is 
described as bilateral absence of edema in either 
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the parietal or the occipital lobes. The frontal 
lobes are often involved. The asymmetric form 
is characterized by unilateral absence of edema in 
either a parietal or an occipital lobe. Finally, in the 
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partial and asymmetric form, there is both absence 
of involvement of either the parietal or the occipital 
lobes and asymmetric abnormalities in the affected 
parietal or occipital lobes.
Complications diagnosed radiologcally at 
presentation of PRES:
Complications diagnosed radiologically at presentation of 
PRES are cerebral ischemia and cerebral hemorrhage (7).
Differential diagnosis:
The non - specific clinical manifestations and 
multiplicity of radiological patterns increase diagnostic 
challenges. Various c ditions may resemble 
PRES, including ictal or post-ictal state (with or 
without status epilepticus), infectious encephalitis, 
progressive multifocal leukoencephalopathy (PML), 
acute disseminated encephalomyelitis, mitochondrial 
myopathy encephalopathy lactic acidosis and stroke-
like episodes syndrome (MELAS), Creutzfeldt-Jakob 
disease, vasculitis, cerebral venous sinus thrombosis, 
and ischemic stroke (watershed or posterior cerebral 
artery territory). The MRI characteristics of these 
conditions are helpful in diagnosis (7).
Treatment
The treatment strategy relates general measures to 
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correction of the underlying cause of PRES. An early 
etiologic diagnosis permits immediate correction of 
the cause of PRES. Patients may need blood pressure 
control, withdrawal of cancer chemotherapy or 
immunosuppressive agents, cesarean section, dialysis, 
or other interventions. Immediate correction of the 
cause is essential to decrease the risk of ischemia or 
bleeding and therefore to prevent permanent disability 
or death. In patients with seizure, anticonvulsant therapy 
is recommended even after a single seizure. Conversion 
of anti-seizure therapy to non-hepatic microsomal 
enzyme-inducing drugs is recommended as soon as 
the clinical condition of the patient stabilizes. Morris 
et al. recommended ceasing the anticonvulsant therapy 
after 3-6 months in uncomplicated cases. They also 
recommended an anticonvulsant regimen for at least 12 
months after the following seizure episode in patients 
with abnormal findings on electroencephalogram or 
cranial MRI and recurrent seizures. Lucchini et al. 
advised anticonvulsant therapy for 12 months in patients 
with brain damage. No consensus has yet been achieved 
about which patients should receive antiepileptic drugs 
for seizures after PRES (1-4, 6,7).
PRES in hematologic-cancer patients
Pediatric patients with hematologic–cancer disease are 
at risk of PRES. Understanding of this syndrome and its 
sequelae in this population is limited by the small number 
of reported patients and by an incomplete understanding 
of the disorder itself. A variety of factors have been 
defined in the etiology of PRES. The most common 
factors in this group of patients are immunosuppressive 
drugs (cyclosporine, anti-thymocyte globulin, 
rituximab, tacrolimus,  interferon) and chemotherapeutic 
agents (methotrexate, L-asparaginase, adriamycin, 
cyclophosphamide, cytosine arabinoside, vincristine). 
Also, sickle cell disease, hypertension, acute blood 
pressure changes, renal failure, tumor lysis syndrome, 
infection, sepsis, shock, andtransplantation (stem cell 
and organ) are some factors that can cause PRES in this 
group of patients (8).
Throughout the treatment of acute childhood leukemia, 
PRES may occur as a complication. Induction 
chemotherapy regimens of acute lymphoblastic leukemia 
(consisting of systemic steroids, repetitive intrathecal 
methotrexate, vincristine, and L-asparaginase) 
may comprise predisposing factors of PRES. 
Asparaginase-induced toxicity or methotrexate-induced 
encephalopathy should be differentiated from PRES 
developing as a complication during the acute leukemia 
treatment. Methotrexate-induced encephalopathy shows 
a tendency to involve the cerebral white matter. In 
addition, methotrexate-induced encephalopathy has a 
tendency to occur in a certain time period, usually a few 
weeks after intrathecal methotrexate infusion. Moreover, 
methotrexate-induced encephalopathy usually involves 
no restriction of diffusion on diffusion MRI. These 
characteristics are helpful in the differential diagnosis of 
chemotherapy-induced leukoencephalopathy and PRES 
(4).
A few cases of PRES related to hematopoietic stem cell 
transplantation (HSCT) in children have been reported. 
Early recognition of PRES and proper management are 
required to decrease the risk of permanent neurological 
disability. In cases of PRES developing as a complication 
after hematopoietic stem cell transplantation, 
immunosuppressive agents and hypertension appear to 
be the main predisposing factors for PRES. Tacrolimus 
and cyclosporine have been considered as predisposing 
factors in PRES. However, the onset of PRES could not 
be associated a certain type of drug, because multiple 
immunosuppressive agents, including tacrolimus, 
cyclosporine, mycophenolate mofetil, and systemic 
steroids were administered simultaneously in various 
combination (4). Heo described a girl who received 
an HLA- identical sibling bone marrow transplant for 
myelodysplastic syndrome with PRES. Endo reported 4 
patients with PRES, which 2 of them had hematologic 
disease. One of them was a case of severe aplastic 
anemia who developed PRES on day 22 after SCT. She 
was on cyclosporine A for Graft-versus-hostdisease 
(GVHD) prophylaxis. After 5 years of follow-up, she 
was complicated with intractable seizure and mental 
retardation (5).
A retrospective chart review by Kim et al. was 
performed on 19 patients aged less than 18 years who 
developed PRES as a complication during treatment 
of acute childhood leukemia. PRES was most often 
observed during acute lymphoblastic leukemia induction 
chemotherapy (n ¼ 9, 47.4%) and after hematopoietic 
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and Ewing sarcoma (n=1). All patients had previously 
taken chemotherapy, and 8 patients were receiving 
remission induction chemotherapy at the time of PRES 
onset. One patient (patient 4) had undergone bone 
marrow transplantation 2 months before PRES onset 
and was taking tacrolimus for treatment of chronic 
GVHD. Six patients were taking steroid therapy at 
the time PRES began, and 6 patients had previously 
received methotrexate. PRES occurred in 8 patients in 
the induction phase of treatment, and all 11 patients 
had hypertension (5 chronically). Seizure activity was 
proximate to cytarabine and tacrolimus administration 
in three patients and further seizures occurred in two 
patients when these medications were re-administrated. 
Coagulation and chemistry studies were normal. The 
white blood cell counts of all patients were normal 
during PRES. Calcium and magnesium levels were also 
normal in all patients. Acute EEG studies of five patients 
were completed; the detected abnormalities included 
nonconvulsive focal status epilepticus (which responded 
to intravenous midazolam), epileptiform activity, and 
background slowing. Concurrent brain MRI demonstrated 
T2 signal abnormalities in all 11 patients, restricted 
diffusion in 4, and hemorrhage in 3. Follow-up MRI 
demonstrated chronic changes consistent with a previous 
hemorrhage in three and evidence of prior parenchymal 
ischemia in one. Three patients developed epilepsy 
and chronic anticonvulsant therapy was continued for 
them. The results of this study showed that PRES is 
an increasingly recognized complication of pediatric 
cancer treatment. Risk factors for PRES in pediatric 
cancer patients were hypertension (not necessarily 
acute) and remission induction chemotherapy. Common 
side effects of cancer treatment, such as hypertension, 
systemic inflammatory response, sepsis, coagulopathy, 
hyperviscosity syndrome, and electrolyte derangement, 
were presumed to negatively affect outcome. Most 
of the patients developed PRES during the induction 
phase of treatment. The reason for this timing has not 
yet been clear. It is likely that unidentified systemic 
factors associated with the induction phase of treatment 
predispose patients to PRES. Endothelial dysfunction 
with subsequent blood–brain barrier disruption is a 
proposed mechanism of PRES and may occur with 
induction treatment uses repetitive systemic and 
stem cell transplantation (n ¼ 8, 42.1%). Nine (47.4%) 
patients developed the complication of PRES during 
acute lymphoblastic leukemia induction chemotherapy. 
The other two patients developed the complication of 
PRES during prophylactic intracranial irradiation therapy 
and maintenance chemotherapy. Among 8 patients with 
the complication of PRES after hematopoietic stem cell 
transplantation, 5 (62.5%) had a history of hypertension. 
In contrast, among 11 patients with the complication of 
PRES without hematopoietic stem cell transplantation, 
only one (9.1%) had a history of hypertension. Moreover, 
unlike other leukemia induction chemotherapy, 
PRES developed only in patients who received acute 
lymphoblastic leukemia induction chemotherapy. PRES 
patients needed long-term anticonvulsant therapy (n 
¼ 9, 50.0%) and manifested intractable seizures (n ¼ 
3, 16.7%). Sequelae were evident in long-term follow-
up MRIs (n ¼ 5, 26.3%). Therefore, it seems that 
acute lymphoblastic leukemia chemotherapy regimens 
comprised the main predisposing factors for PRES 
complicated during induction chemotherapy, compared 
to hypertension and immunosuppressive agents after 
hematopoietic stem cell transplantation (4).
Incecik et al. reported 9 cases of PRES (7 boys and 2 girls) 
with mean age of 7.78±3.76 years (ranging 3-13 years). 
The main etiologies were as follows: taking intrathecal 
methotrexate for acute lymphoblastic leukaemia 
(ALL-L2) in two patients; taking cyclosporine for 
allogeneic bone marrow transplantation for thalassemia 
in another two patients; taking intrathecal cytarabine 
(Ara-C) for acute myeloblastic leukemia (AML) in one 
patient; taking cyclophasphamide for nonHodgkin’s 
lymphoma in one patient, taking IVIG for guillain-barré 
syndrome (GBS) in one patient; and the last two patients 
had acute hypertensive crisis and chronic renal failure. 
Importantly, 7 children were normotensive and were 
not hypertensive at presentation and follow-up. PRES 
resolved completely in all of the patients (12).
Morris et al. reported 11 patients (7 females) who 
had radiological and clinical features consistent with 
PRES and were under treatment for cancer at St. Jude 
Children’s Research Hospital between January 1995 
and January 2005. The average age of them at the time 
of PRES onset was 10.4 years. Primary diagnoses were 
acute leukemia (n=8), non-Hodgkin lymphoma (n=2), 
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pattern occurred as frequently as the parietal-occipital 
one. In 38% of cases, residual lesions were encountered 
with focal laminar necroses which are most frequent. 
Initial clinical syndromes associated with PRES were: 
seizures in 18, altered mental state in 5, and hemiparesis 
and visual disturbances in 2 children. Mean arterial 
blood pressure at the onset of PRES was 140/85 mmHg 
(IQR systolic: 124-169, diastolic: 78-93 mmHg). He 
concluded that pediatric PRES in this cohort comprises a 
broad radiological and clinical spectrum. The occurrence 
of frontal lesions, a superior frontal sulcus associated 
lesion pattern, and the development of focal laminar 
necrosis seem to be common in children (3).
So, considering of PRES in hematologic-oncologic 
patients with neurologic symptoms including seizures 
episodes is advised, and evaluation by MRI images, 
especially FLAIR sequences has the most accurate 
diagnostic value.
Case presentation 
The patient is a 7-year old boy with a history of 
thrombocytopenia, then progression to direct 
and indirect coombs positive immune hemolytic 
anemia. Based on evaluation and diagnosis of Evans 
syndrome during the course of disease, he received 
different immunosuppressive treatments, including 
corticosteroids (prednisone and pulse therapy of 
methylprednisolone), cyclosporine, IVIG, and blood 
transfusion. He was refractory to treatment and had 
been dependent on blood transfusion. He was on blood 
transfusion every other day. On May 2012, 4 months 
after the onset of the disorder, he was referred to our 
Hematology Department. At the time of presentation, 
he had cushingoid face, pallor (RBC:1.890000/mm3, 
Hb: 5.4 gr/dl, MCV: 86 fl, Platelet: 129000/mm3, 
Reticulocyte: 10%), jaundice (BilT: 7.8 mg/dl, BilD: 
2 mg/dl) and splenomegaly (169 mm). Complementary 
evaluations, including virology tests and collagen 
vascular tests were negative. Direct and indirect coombs 
tests as well as antibody screening tests were positive 
for both IgG and C3d. Bone marrow aspiration  revealed 
erythroid hyperplasia and flow cytometry was normal. 
We started treatment with rituximab 375 mg/m2/week 
for 4 weeks and cyclosporine 7 mg/kg/day in divided 
doses (Q8h) in addition to corticosteroid. After 4 courses 
intrathecal administration of chemotherapy. Endothelial 
dysfunction may also account for the increased incidence 
of hemorrhage in this group of patients being treated for 
AML. MR images often show atypical findings, some of 
which are irreversible. A significant number of patients 
develop epilepsy despite clinical and radiographic 
evidence of recovery. Won reported 8 patients with 
PRES; 4 of them had acute lymphocytic leukemia, 1 had 
aplastic anemia, and 3 had solid tumors (1 patient each 
for neuroblastoma, Ewing sarcoma, and osteosarcoma). 
Allogeneic stem cell transplantation was done in 2 
patients. Immunosuppressive agents, such as tacrolimus 
and cyclosporine A were used in 3 patients. One 
neuroblastoma patient was in immediate postoperative 
status. All patients experienced seizure attacks of 
different types and showed typical MRI findings. 
Follow-up MRIs revealed significant improvements. 
From this review, chemotherapy and surgery might 
be considered as additive causes for PRES other than 
immunosuppressive agents. Thus, careful examination 
of the patients receiving chemotherapy and surgery was 
required to find out this uncommon but good prognostic 
complication (16).
Lucchini described that encephalopathy syndrome 
in children with hemato-oncological disorders is not 
always posterior and reversible. He presented 12 
cases of PRES in children who underwent intensive 
chemotherapy regimens. All patients survived the acute 
event which showed a clinical recovery of the acute 
neurological signs in 1–3 days and normalization of the 
pattern of EEG in a period ranging from 1 to 8 months. 
During long-term follow-up, 4 patients developed 
either clinical impairment or EEG-MRI anomalies. 
He suggested that a long-term follow-up is required to 
determine the reversibility of the neurological events. 
Clinical observation, as well as EEG and MRI should be 
considered in follow-up evaluations. Siebert  reported 18 
pediatric patients with PRES with mean age 9 years (IQR 
7-12). Most common predisposing causes were renal 
and haemato-oncologic diseases frequently associated 
with endotheliotoxic cytostatic medication. After 5 
years of Follow-up, she had complicated intractable 
epilepsy and mental retardation. Frontal lesions occurred 
as commonly as parietal lesions followed by occipital 
lesions. The superior frontal sulcus topographic lesion 
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of rituximab, the patient showed a very good response to 
the treatment. Anemia and icterus improved and blood 
transfusion was stopped. So, in this phase, tapering of 
corticosteroids was started and mycophenolate mofetil 
(MMF) was added to the treatment. The patient was on 
follow-up and he was clinically stable. 
Two months later during follow up and treatment 
with cyclosporine, MMF, and tapered prednisone, 
he presented to emergency department with seizure 
episodes without fever. His blood pressure was 140/90. 
His CBC was as follows: WBC 2700/mm3, Hb 11.3 gr/
dl, platelet 68000/mm3, reticulocyte count 4.5%. PT, 
PTT, and biochemistry tests including BS, Ca, and Mg 
were normal. He was admitted to PICU. Anticonvulsant 
therapy, including diazepam, phenytoin, phenobarbital, 
and supportive therapy was started. Brain CT and MRI, 
MRV, and MRA were performed. Lesions were in favour 
of PRES in occipital area. EEG was normal. Based on 
diagnosis of PRES, cyclosporine was discontinued. 
Tapering and stopping of MMF were started and then 
treatment was changed to azathioprine. One month later, 
brain MRI was performed and was completely normal. 
He was clinically stable and treatment with azathioprine, 
low dose corticosteroid, and phenobarbital was 
continued. Because of history of long-term treatment 
with corticosteroids, bone mineral densitometry and 
endocrine consultation were done, and the patient 
received pamidronate. 
He was on follow-up until 2 months later, when he 
was admitted again because of severe back pain and 
low grade fever. He was not able to walk. Imaging 
evaluation including lumbosacral MRI revealed 
spondylodiscitis and collapse of L2-L3 vertebrae. Based 
on history of immunosuppressive therapy and fever, 
antibiotic treatment was started and consultations with 
orthopedic and neurosurgeon teams were done. First, 
biopsy sampling with CT guide was done, but the result 
of sampling was not conclusive and revealed just an 
inflammatory processes. Use of a lumbosacral cast was not 
effective. During admission, the patient developed high 
persistent fever and pancytopenia. At this time, complete 
evaluation was done. The results of blood cultures, PCR 
assay for mycobacterium tuberculosis, and virology 
tests, including Parvovirus B19, HIV, HbsAg, HbsAb, 
CMV, and EBV were negative. Bone marrow aspiration 
showed severe hypo-cellular marrow. He received IVIG 
and GCSF, in addition to wide spectrum antibiotic 
therapy. Because of persistent pancytopenia and fever, 
imaging for evaluation of fungal infection including 
chest CT was done. The CT report was suggestive of 
fungal infection. The result of galactomannan test was 
negative. Treatment with liposomal amphotericin B 
was started, but because of the persistent fever and no 
response to liposomal amphotericin B, voriconazole was 
added to the treatment. 
The patient had a neurosurgical intervention because of 
progression of paresthesia and paraplegia. Open surgery 
and tissue sampling from the site of lumbar lesions 
showed fungal invasion of bone (Aspergillosis). Tissue 
sampling for malignancy was negative. Also, PCR 
assay for Mycobacterium tuberculosis was negative. 
Unfortunately, treatment with combination therapy of 
antifungal drugs was not effective and the patient died 1 
year after the onset of disease on March 2013. 
In conclusion, PRES is a clinico-neuroradiological 
disease entity representing with characteristic MRI 
findings of subcortical/cortical hyperintensity in T2-
weighted sequences, more often observed in parietal-
occipital lobes, accompanied by clinical neurologic 
alterations. PRES is a rare central nervous system 
complication in child hematologic-oncologic patients 
and presents with various neurological symptoms, 
ranging from numbness on extremities to a generalized 
seizure. As a result, careful examination of patients 
receiving chemotherapy, immunosuppressive therapy, 
and surgery was required to find out this uncommon but 
good prognostic complication.
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